BTIG Research Lowers Personalis (NASDAQ:PSNL) Price Target to $11.00

Personalis (NASDAQ:PSNL) had its price target dropped by stock analysts at BTIG Research from $13.00 to $11.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price target suggests a potential upside of 83.95% from the company’s previous close.

Several other equities research analysts have also commented on the stock. Guggenheim boosted their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Morgan Stanley decreased their target price on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 5th. Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Needham & Company LLC boosted their target price on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $11.17.

Personalis Price Performance

NASDAQ:PSNL opened at $5.98 on Monday. The firm’s fifty day moving average price is $6.93 and its 200 day moving average price is $8.23. Personalis has a 1-year low of $3.84 and a 1-year high of $11.50. The firm has a market cap of $626.23 million, a price-to-earnings ratio of -5.86 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The firm had revenue of $15.47 million during the quarter, compared to analysts’ expectations of $14.49 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. As a group, analysts expect that Personalis will post -1.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd raised its stake in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after buying an additional 1,479 shares during the last quarter. Legal & General Group Plc acquired a new position in shares of Personalis during the 2nd quarter worth $30,000. International Assets Investment Management LLC acquired a new position in shares of Personalis during the 4th quarter worth $31,000. BNP Paribas Financial Markets raised its stake in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares during the last quarter. Finally, Focus Partners Wealth acquired a new position in shares of Personalis during the 1st quarter worth $47,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.